Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for LOPINAVIR; RITONAVIR
- First in Human Study of TLC-ART 101 (ACTU 2001)
- Lopinavir/Ritonavir in PLWH With High-Grade AIN
- Rifapentine and Isoniazid TB Preventive Therapy (3HP) for Children Taking Dolutegravir-based Antiretroviral Treatment (DOLPHIN KIDS)
- Adding Colchicine to Tocilizumab in Patients With Severe COVID-19 Pneumonia.
- Strategies to Reduce Mortality Among HIV-infected and HIV-exposed Children Admitted With Severe Acute Malnutrition
- Masitinib in Patients With Symptomatic Mild to Moderate COVID-19
- Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)
- Evaluation of The Efficacy of Triazavirin Versus Oseltamivir in Egyptian Patients Infected With COVID-19
- Ivermectin Versus Standard Treatment in Mild COVID-19
- Effectiveness of Remedesvir in COVID-19 Patients Presenting at Mayo Hospital Lahore
- Hydroxychloroquine for Treatment of Non-Severe COVID-19
- The Effects of Acupuncture in Overcoming Inflammatory Response to COVID-19 Mild-moderate Symptoms
- Comparative Therapeutic Efficacy and Safety of Different Antiviral and Anti Inflammatory Drugs in COVID-19 Patients.
- Safety & Efficacy of Low Dose Aspirin / Ivermectin Combination Therapy for Treatment of Covid-19 Patients
- Comparison of Remdesivir Versus Lopinavir/ Ritonavir and Remdesivir Combination in COVID-19 Patients
- Efficacy of Favipiravir in Treatment of Mild & Moderate COVID-19 Infection in Nepal
- Inhaled Ivermectin and COVID-19
- Study to Investigate the Treatment Effect of Colchicine in Patients With COVID-19
- IFN-beta 1b and Remdesivir for COVID19
- World Health Organization (WHO) COVID-19 Solidarity Trial for COVID-19 Treatments
- Study to Investigate the Benefits of Colchicine in Patients With COVID-19
- Efficacy and Safety of Direct Anti HCV Drugs in the Treatment of SARS-COV-2 (COVID-19)
- Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection
- Daily Regimen of Tenofovir/Emtricitabine as Prevention for COVID-19 in Health Care Personnel in Colombia
- HIV-1 Infected Patients, Phase II Trial, Dual Combination Doravirine/Raltegravir Open Label
- FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals
- IFN Beta-1b and Ribavirin for Covid-19
- Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy
- Efficacy and Safety of Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate Disease and in COVID-19 Asymptomatic Patients
- Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial
- Dual Therapy With Interferon Beta-1b and Clofazimine for COVID-19
- Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year
- Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19 (ANA-COVID-GEAS)
- Efficacy and Safety of Anti HCV Drugs in the Treatment of COVID-19
- Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19
- Evaluation of Additional Treatments for COVID-19: a Randomized Trial in Niger
- Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: "The Hope Coalition - 1"
- Study on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of Bangladesh
- Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment
- Baricitinib Compared to Standard Therapy in Patients With COVID-19
- Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus
- Favipiravir vs Hydroxychloroquine vs Control in COVID -19
- Bioequivalence Study of Lopinavir/Ritonavir 200/50 mg Film Tablet (World Medicine Ilac, Turkey) Under Fasting Conditions
- Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19
- Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial
- Randomised Evaluation of COVID-19 Therapy
- Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19
- Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19
- Max Ivermectin- COVID 19 Study Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study
- Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19
- Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19
- OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome
- Tocilizumab Treatment in Patients With COVID-19
- Isotretinoin in Treatment of COVID-19
- Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia
- Baricitinib Therapy in COVID-19
- Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection
- Treatment for COVID-19 in High-Risk Adult Outpatients
- Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)
- Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)
- Umifenovir in Hospitalized COVID-19 Patients
- Interferon Beta 1a in Hospitalized COVID-19 Patients
- Trial to Study the Benefit of Colchicine in Patients With COVID-19
- Double Therapy With IFN-beta 1b and Hydroxychloroquine
- Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19
- Convalescent Plasma Therapy vs. SOC for the Treatment of COVID-19 in Hospitalized Patients
- An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial
- The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients.
- Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers
- COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With COVID-19
- COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir
- Trial of Treatments for COVID-19 in Hospitalized Adults
- Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)
- Efficacy and Safety of IFN-α2β in the Treatment of Novel Coronavirus Patients
- The Clinical Study of Carrimycin on Treatment Patients With COVID-19
- A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection
- Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment
- Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection
- A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia
- The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection
- Treatment and Prevention of Traditional Chinese Medicines (TCMs) on COVID-19 Infection
- Lopinavir/r/ Lamivudine/ Abacavir as an Easy to Use Paediatric Formulation
- HIV Diagnosis and Treatment at Birth for Newborn With High Risk HIV Exposure
- RESIST-2: 2nd-line ART for HIV-2 Infection
- Phase 4 Study of Dolutegravir (DTG) in Russian Federation
- MERS-CoV Infection tReated With A Combination of Lopinavir /Ritonavir and Interferon Beta-1b
- Clinical Trial to Evaluate Drug-drug Interactions Between Darunavir/Cobicistat and Etravirine in Hiv- Infected Patients
- Evaluation of Low-dose Darunavir in a Switch Study
- The Effectiveness of Dual Therapy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Russian Federation
- Bioequivalence Study of CRushed TriUMeq With or Without Drip Feed Compared to the Whole Tablet
- Pharmacokinetics and Safety of Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice Weekly
- PK TDF in Thai HIV-infected Children
- Test Albuvirtide in Experienced Patients
- Pharmacokinetics of Lopinavir/Ritonavir Superboosting in Infants and Young Children Co-infected With HIV and TB
- Effects of Altered Formulation on the Bioequivalence of Tacrolimus in Healthy Female and Male Volunteeers
- Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-S
- Early cART and cART in Combination With Autologous HIV-1 Specific Cytotoxic T Lymphocyte (CTL) Infusion in The Treatment of Acute HIV-1 Infected Adults
- Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line Treatment
- Study on the Impact of Triptolide Woldifiion on HIV-1 Reservoir In Acute HIV-1 Infection
- Comparison of Two Combinations in Antiretroviral Post-Exposure Prophylaxis for HIV-1: Tenofovir/Emtricitabine (Truvada ®) + Lopinavir/Ritonavir (Kaletra ®) vs Tenofovir/Emtricitabine/Cobicistat/Elvitegravir (Stribild ®). Prospective, Randomized,
- Study Assessing the Effects of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy Participants
- Efficacy and Safety Study of Darunavir for the Treatment of HIV/AIDS
- First-Line Treatment for HIV-2
- Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission
- ATAGLU: Study of Glucose Metabolism in HIV Positive Patients That Switch From Another Protease Inhibitor to Atazanavir
- Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil
- Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions
- IMPAACT P1092: Steady State PK in Malnourished HIV Infected Children
- Nevirapine vs Ritonavir-boosted Lopinavir in ART Naive HIV-infected Adults in a Resource Limited Setting
- Hepatitis C Virus Post-Exposure Prophylaxis for Health Care Workers
- A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects
- A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects.
- Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin
- EARNEST Rifabutin Pharmacokinetics (PK) Substudy
- Drug-drug Interaction Study Between Lopinavir/Ritonavir and Isavuconazole
- Atazavanir/Ritonavir-based HAART in Children
- Optimal Dosing of 1st Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study)
- Comparing PI-Based to a nNRTI-based ART for Clearance of Plasmodium Falciparum Parasitemia in HIV-Infected
- Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
- Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV
- Pilot Simplification Study to Lopinavir/Ritonavir 800/200 mg Monotherapy Regimen Once Daily
- Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP)
- Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin
- Prospective Evaluation of Etravirine for HIV-infected Patients in Need of Lipid-lowering Drugs
- Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1:FOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC (MARAVI-PEP)
- Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection
- Impact of Raltegravir Intensification on HIV-1-infected Subjects With Complete Viral Suppression Under Monotherapy With Protease Inhibitors
- Antiretroviral Drug Interaction Study in Volunteers With HIV
- Study to Evaluate the Activity and Tolerability of Lopinavir/Ritonavir and Lamivudine Bitherapy in HIV Patients With Viral Suppression
- RAltegravir Switch STudy: Effects on Endothelial Recovery
- A Study on Antiretroviral Therapy (ART) Naïve Patients On Different Regimens to Treat Hiv (NORTHIV)
- Study of Options for Second-Line Effective Combination Therapy (SELECT)
- Pediatric Study for Appropriate Dose of Ritonavir Boosted Lopinavir in Thai HIV-infected Children (PEARL)
- Pharmacokinetic Interactions Between DMPA and LPV/r Among HIV-Infected Women
- Comparing Continuing Tenofovir, Emtricitabine (or Lamivudine) Plus Lopinavir and Switching to Raltegravir Plus Darunavir
- Dosing, Safety and Pharmacokinetic Profile of Rifabutin in Children Receiving Concomitant Treatment With Kaletra
- A Multicentre Trial of Second-line Antiretroviral Treatment Strategies in African Adults Using Atazanavir or Lopinavir/Ritonavir
- Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries
- Study of Lopinavir/ Ritonavir and Lamivudine Versus Standard Therapy in Naïve HIV-1 Infected Subjects.
- Hydroxychloroquine for Discordant CD4 Responders on Highly Active Antiretroviral Therapy (HAART)
- Depot Contraception With and Without Lopinavir/Ritonavir
- Pharmacokinetic Interactions Between an Herbal Medicine (African Potato) and Antiretroviral Agents (Lopinavir/Ritonavir)
- KONCERT A Kaletra ONCE Daily Randomised Trial of the Pharmacokinetics, Safety and Efficacy of Twice-daily Versus Once-daily Lopinavir/Ritonavir Tablets Dosed by Weight as Part of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-1 (
- PI or NNRTI as First-line Treatment of HIV in West Africa - the PIONA Trial
- Maintenance Boosted Lopinavir Monotherapy Following Salvage Protease-inhibitor (PI) Based Regimen in HIV With Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) Based Regimen Failure
- A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines
- Lopinavir and Ritonavir in Improving Immune Response to Vaccines in Patients With Complete Remission Following A Bone Marrow Transplant for Hodgkin Lymphoma
- Lopinavir (LPV) Dose Reduction
- Effects of Intensive cART During Acute/Early HIV Infection
- The Influence of Ritonavir, Alone and in Combination With Lopinavir, on Fenofibric Acid Pharmacokinetics in Healthy Volunteers
- Treatment Options for Protease Inhibitor-exposed Children
- Pharmacokinetics (PK) and Safety of 2 Different Doses of Lopinavir/Ritonavir in in HIV/Tuberculosis (TB) Co-infected Patients Receiving Rifampicin Containing Anti-tuberculosis Therapy
- Safety Study of a Tenofovir-containing Drug Regimen for the Prevention of Mother-to-child Transmission of HIV and HBV
- Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma
- Clinical Study of an Aluvia-based HAART Regimen for Prevention of Mother-to-child HIV Transmission in Africa
- Evaluation of Kaletra Therapy Over the Long-term
- Special Investigation of Kaletra in Pregnant Women
- Drug Use Investigation of Kaletra
- Clinical, Virological and Safety Outcomes of a Lopinavir/Ritonavir-Based Regimen in HIV-1 Infected Patients in Routine Clinical Use in China
- Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study)
- Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries
- Drug-Drug Interaction of Lopinavir/Ritonavir on Pitavastatin
- Fosamprenavir in Pts With Hepatic Impairment
- Lopinavir/Ritonavir or Efavirenz as First-line Antiretroviral Therapy
- Analysis of Changes in Adipose Tissue of Patients With Lipoatrophy HIV Infection Treated With Nucleoside Thymidine, After Switching to Monotherapy With Lopinavir / Ritonavir
- Ritonavir-boosted Lopinavir Monotherapy
- Clinical Study to Evaluate the Efficacy and Safety of Lopinavir/Ritonavir Monotherapy Versus Darunavir/Ritonavir Monotherapies as Simplification Switching Strategies of PI/NNRTI-Triple Therapy Based-Regimens
- Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women
- Pharmacokinetics of Lopinavir/Ritonavir at Three Different Doses.
- Pilot Assessment of Lopinavir/Ritonavir and Maraviroc
- Immune-based Therapy Pilot Study for the Treatment of Primary HIV Infection (PHI-IMD).
- Pilot Trial of Statin Use in Burn Patients
- Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients
- HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children
- Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV Subjects
- Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients
- Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations for HIV-1 PMTCT in Pregnant and Breastfeeding Women : a Phase 3 Trial
- A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen
- Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)
- Drug Interaction Study of Darunavir/Ritonavir and Lopinavir/Ritonavir on GSK2248761 PK and CYP450 Probe Drugs
- Dose Reduction of Lopinavir in Children
- Efficacy and Safety of Single Versus Double Ritonavir-boosted Protease Inhibitor (PI)-Based Antiretroviral Therapy (ART) Regimens
- Pharmacokinetic Interaction Between the Antimalarial Combination Artemether/Lumefantrine and Combination Antiretroviral Therapy Including Lopinavir/Ritonavir in HIV-infected Adults
- GSK1349572 Drug Interaction With Etravirine and Either Darunavir/Ritonavir or Lopinavir/Ritonavir
- Treatment of HIV/HCV Coinfection With Peg-IFN and Ribavirin in Patients Receiving ART Monotherapy With Lopinavir/r
- Prevention of Lipoatrophy in Patients Treated With Lopinavir/Ritonavir in Monotherapy Versus ZDV + 3TC + ABC
- Lopinavir/r Monotherapy Versus Abacavir/Lamivudine and Lopinavir/r for Limb Fat Recovery in Persons With Lipoatrophy
- Drug Interaction Study Between Eltrombopag and Lopinavir/Ritonavir in Healthy Adult Subjects.
- TMC207-TiDP13-C110: Interaction Study With Lopinavir/Ritonavir in Healthy Volunteer
- Lopinavir/Ritonavir (Kaletra) PK in Children
- TDM of Generic Lopinavir/Ritonavir 200/50 mg
- Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease
- GSK1349572 Drug Interaction Study With Protease Inhibitors
- ROCKET II - Randomized Open Label Switch for Cholesterol Elevation on Kivexa + Kaletra Evaluation Trial
- An Evaluation of the Pharmacological Interaction of Lopinavir/r and Rifampin
- TMC125-TiDP2-C197: A Phase I Trial to Investigate the Pharmacokinetic Interaction Between Lopinavir/Ritonavir and TMC125 Both at Steady-state in Healthy Volunteers.
- NNRTI/PI Toxicity Switch to Darunavir Study
- Comparison of Liquid Kaletra and Low Dose Kaletra Tablets
- Effects of 2 Initial Standard Antiretroviral Combinations Therapies on Lipid Metabolism
- Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r
- Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients
- Safety Study of Lopinavir/Ritonavir With Raltegravir in HIV-infected Patients
- A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects
- Safety and Efficacy Study of Switching From Epzicom to Truvada
- GSK706769/KALETRA Drug-drug Interaction Study
- Effect of the HIV Protease Inhibitors Atazanavir and Lopinavir/Ritonavir on Cardiovascular Disease Risk Factors
- Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)
- Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir
- Kaletra-isentress Treatment Evaluation
- Pharmacokinetic Interactions Between Antiretroviral Agents and Antimalarial Drug Combinations
- Kaletra and Viread in Antiretroviral Naïve Patients
- Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive Patients
- Pharmacokinetic Study of Two Generic Co-formulations of Lopinavir/Ritonavir for HIV Infected Children (SURF)
- Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects
- Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding
- Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals
- Second-line Therapy Antiretroviral in Patients Who Failed Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) - Based Regimens
- Lopinavir/Ritonavir Monotherapy in Children
- Pharmacokinetics of Low Dose Ritonavir
- Pharmacokinetics of Generic Lopinavir/Ritonavir in Pregnant Women
- Drug Interaction Study Between Lumefantrine and Lopinavir/Ritonavir
- Determining the Effects of Observed and Self-Administered Drug Regimens in HIV Infected Adults
- A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory Syndrome
- Pharmacokinetic Interactions Between Buprenorphine and Kaletra (Lopinavir/Ritonavir)
- Raltegravir Kaletra Pharmacokinetics
- Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl
- Raltegravir Insulin Sensitivity Study
- HIV - Monotherapy in Switzerland (MOST-ch)
- HIV Antiretroviral Drugs and Metabolism
- Kaletra Monotherapy in HIV/HCV Co-infected Subjects
- Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO)
- Pharmacokinetic and Efficacy of SQV/r 1500/100 Plus Tenofovir/Emtricitabine 300/200 mg
- A PK and Salvage Study for Children With HIV-infection
- Drug Interaction Study of Lopinavir/Ritonavir and Gemfibrozil
- Anti-Retrovirals for Kaposi's Sarcoma
- Lopinavir Capsules to Kaletra or Invirase Tablets
- Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Patients Starting Treatment With Anti-Hepatitis C Virus (HCV) Therapy
- Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Antiretroviral (ARV) Naive Patients Starting Treatment With Anti-HCV Therapy
- Optimizing Pediatric HIV-1 Treatment, Nairobi, Kenya
- Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya
- Prevention of HIV1 Mother to Child Transmission Without Nucleoside Analogue Reverse Transcriptase Inhibitors in the Pre-partum Phase. ANRS 135 Primeva
- Drug Interaction Study Between Atovaquone and Antiretroviral Agents in HIV-1 Infected Patients
- Pharmacokinetic Study of Two HIV Protease Inhibitors in Patients
- Safety and Effectiveness of Short-Term Anti-HIV Drug Therapy for Recent HIV-1 Infection
- BOOST: Study of Increased Dosage of Lopinavir/Ritonavir (LPV/r)
- Metabolic Effects of Switching Kaletra to Boosted Reyataz
- Maternal/Infant Peripartum NVP, Versus Infant Only Peripartum NVP, or Maternal LPV/r in Addition to Standard ZDV Prophylaxis for the Prevention of Perinatal (PMTCT) HIV in Thailand
- The Pharmacokinetics of Double Boosted Protease Inhibitors in Antiretroviral-naive HIV-1 Infected Patients
- Immune Reconstitution in naïve HIV Patients With CD4 <100 Cells/mL When Treated With Lopinavir or Efavirenz.
- Atazanavir or Lopinavir in HIV Post-exposure Prophylaxis
- Saquinavir/Ritonavir in Single Therapy as Maintenance Treatment
- Study of Lopinavir/Ritonavir Tablets Comparing Once-Daily Versus Twice-Daily Administration When Coadministered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced Human Immunodeficiency Virus Type 1 Infected Su
- Safety and Effectiveness of Lopinavir/Ritonavir in Individuals Who Have Failed Prior HIV Therapy
- Pilot Study of Effect of Kaletra on CD4 Response in HIV Positive (+) Patients With Viral Suppression KIMBO Study
- Antiretroviral Therapy for Advanced HIV Disease in South Africa
- Study on the Effect of Kaletra + Nevirapine as Maintenance Bitherapy Compared to a Triple Therapy Including Kaletra + Analogues in HIV Patients
- A Phase IV Study of BMS-232632 in HIV+ Patients With Metabolic Syndrome
- Antiviral Responses to NNRTI-Based vs. PI-Based ARV Therapy in HIV Infected Infants Who Have or Have Not Received Single Dose NVP for Prevention of Mother-to-Child Transmission of HIV
- A Multicenter Study to Assess the Tolerability of Once Daily Lopinavir/Ritonavir (LPV/r) Liquid Versus Capsules
- BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada
- Trizivir Vs. Kaletra and Combivir for the Prevention of Mother-to-Child Transmission of HIV
- Drug Interaction Study Between Antimalarial and Anti-HIV Medications
- Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected
- TMC114-C211: Trial of an Investigational Protease Inhibitor TMC114 With Ritonavir ("TMC114/r") in HIV-1 Infected Patients Who Have Never Been Treated With Antiretroviral Medications.
- Evaluation of Two Anti-HIV Treatment Strategies in Resource-Limited South African Communities
- High Dose Ritonavir/Lopinavir Liquid Formulation in Salvage Therapy for Protease Inhibitor Resistant HIV Disease
- Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV
- Safety of Lopinavir/Ritonavir (Kaletra) in HIV/HCV Co-infected Subjects vs Baseline Liver Biopsy Metavir Score
- Efficacy and Safety of Kaletra Monotheraphy Compared to Kaletra Based Triple Therapy to Treat HIV in Antiretroviral Naїve Patients
- Efficacy of Simplified Two Drug Kaletra Regimen vs. Kaletra Triple Drug Standard of Care Regimen in Treatment naïve HIV Infected Patients
- When to Start Anti-HIV Drugs in Children Infected With HIV (The PREDICT Study)
- SNAP: Switching Nucleoside Analogues Protocol - Lipoatrophy and Mitochondrial Function
- Salvage Therapy With Amprenavir, Lopinavir and Ritonavir in HIV-Infected Patients in Virological Failure.
- Pharmacokinetic Study of Rosuvastatin and Lopinavir/Ritonavir in HIV Patients
- PI Vs. NNRTI Based Therapy for HIV Advanced Disease
- Atazanavir or Boosted Atazanavir Substitution for Ritonavir Boosted PI in Patients With Hyperlipidemia
- Induction-maintenance of Lopinavir/r in HIV-infected Subjects
- A Pharmacokinetic (PK) Study of a Combination of Indinavir, Ritonavir, and Amprenavir
- Kaletra Sex/Gender Pharmacokinetics (PK) Study
- A Research Study to See if a Change in Therapy for HIV Infection Can Improve the Immune Response to Treatment
- Open Label Study of 908/RTV in Combination With Other PIs for the Treatment of Multi PI-Experienced HIV Subjects
- A Randomised Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir (TPV) Plus 100 mg or 200 mg Ritonavir (RTV) p.o. BID in Comparison to 400 mg Lopinavir (LPV) Plus 100 mg RTV p.o. BID in Combination With Standard B
- NRTI-Sparing Pilot Study
- Comparison of Treatment Simplification by LPV/r vs Current Treatment Continuation in HIV-Infected Patients
- Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir.
- A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen
- Drug Interactions Between Lopinavir/Ritonavir and Oral or Patch Contraceptives in HIV Infected Women
- MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS)
- A Study Exploring an Induction-Maintenance Kaletra-Based Therapy Versus a Sustiva-Based Regimen in Previously Non-Treated, HIV-1/HCV Co-Infected Subjects
- Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir
- Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125)
- Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults
- Study of the 48-Week Virologic and Immunologic Response to Lopinavir/Ritonavir (Kaletra) in HIV Positive Adult Patients
- "OK 2004 Study" (Only Kaletra 2004 Study): Study to Evaluate Suspending Nucleosides From Triple-Drug Therapy in HIV Subjects
- TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
- Reducing the Incidence of Nevirapine Resistance Mutations in Pregnant HIV Infected Women Who Receive Anti-HIV Drugs Prior to and After Giving Birth
- GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection
- Drug Interactions of Echinacea, Ginseng, and Ginkgo Biloba Taken With Lopinavir/Ritonavir in Healthy Volunteers
- Differences in Blood Levels of Lopinavir/Ritonavir in HIV Infected Men and Women
- Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth
- GW873140 In Combination With Kaletra In HIV Infected Subjects
- A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy
- A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With
- Anti-HIV Treatment Interruptions in HIV Infected Adults in South Africa
- Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults
- Comparison of Three Anti-HIV Regimens to Prevent Nevirapine Resistance in Women Who Take Nevirapine During Pregnancy
- Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV
- NNRTI vs PI Regimens for HIV Infected Women After They Have Taken Nevirapine to Prevent Mother-To-Child HIV Transmission
- Comparison of Anti-HIV Drug Combinations to Prevent Mother-to-Child Transmission of HIV
- KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks
- Cyclosporine A in Combination With Abacavir Sulfate, Lamivudine, and Zidovudine and Lopinavir/Ritonavir in HIV
- Safety of Saquinavir and High Doses of Lopinavir/Ritonavir in Children With HIV
- Strategies for Delivering Anti-HIV Therapy in South Africa
- The Effect of Lopinavir/Ritonavir on Endothelial Function
- Anti-HIV Drug Regimens With or Without Protease Inhibitors and Drug Level Monitoring in HIV Infected Adolescents
- A Simplified Kaletra® (Lopinavir/Ritonavir)-Based Therapy Versus a Sustiva® (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects
- Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients
- When to Start Anti-HIV Drugs in Patients With Opportunistic Infections
- Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive Patients
- Comparing Standard-Dose Versus Adjusted-Dose Lopinavir/Ritonavir Therapy in HIV-Infected Persons With Drug Resistance
- Hormone Replacement Therapy and Anti-HIV Drugs in HIV-Infected, Postmenopausal Women
- Study of Lopinavir, Ritonavir, Tenofovir and Emtricitabine in HIV-Infected Antiretroviral Naïve Subjects
- Lopinavir/Ritonavir in Combination With Saquinavir Mesylate or Lamivudine/Zidovudine to Explore Metabolic Toxicities in Antiretroviral HIV-Infected Subjects
- Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children
- Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra as Their Second Protease Inhibitor
- Safety and Effectiveness of Lopinavir/Ritonavir in HIV Infected Infants
- A Study to Compare Anti-HIV Drugs Given Twice a Day or Once a Day, With or Without Direct Observation
- Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV
- Study of Anti-HIV Therapy Intensification
- Therapeutic Drug Monitoring and Viral Resistance Testing in the Treatment of HIV-Infected Children
- Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People
- Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients
- Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s)
- Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV
- Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure
- Effect of a Change in HIV Therapy on Liver Steatosis, Inflammation, and Fibrosis
- Emtricitabine Given Once A Day With Other Anti-HIV Drugs in Children With HIV
- Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen
- A Study of HIV-Disease Development in Aging
- ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Naïve HIV-Infected Subjects
Clinical trials list
click for details